Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Remdesivir AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
170 results
  • Emerging pharmacotherapies for COVID-19. [Review]
    Biomed Pharmacother. 2020 May 14; 128:110267.Salvi R, Patankar P
  • Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 d…
  • Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. [Review]
    Pharmacol Ther. 2020 May 26 [Online ahead of print]Liu T, Luo S, … Shi GP
  • The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine, and traditional Chinese medicine. There are over 2118 on-going clinical trials underway, but to d…
  • The COVID-19 pandemic: is our medicine still evidence-based? [Journal Article]
    Ir J Med Sci. 2020 May 28 [Online ahead of print]Deana C
  • There is no randomized controlled trial that demonstrated the efficacy of antiviral therapy against COVID-19 yet. However, physicians are prescribing different drugs to a large part of COVID-19 population in the hope they will cure them. This does not reflect the evidence-based medicine approach. What we need is more evidence-based knowledge about what routine care practices we should to apply to…
  • Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. [Journal Article]
    Drug Saf. 2020 May 28 [Online ahead of print]Davies M, Osborne V, … Shakir S
  • CONCLUSIONS: Preliminary clinical trial results suggest that there may be a favourable benefit-risk profile for remdesivir compared with placebo in severe COVID-19 infection and further data on benefits would strengthen this evaluation. There is limited safety data for remdesivir, which should be obtained in further studies. The current framework summarises the key anticipated benefits and risks for which further data are needed. Ongoing clinical trial data can be incorporated into the framework when available to provide an updated benefit-risk assessment.
  • A computational prediction of SARS-CoV-2 structural protein inhibitors from Azadirachta indica (Neem). [Journal Article]
    J Biomol Struct Dyn. 2020 May 28 [Online ahead of print]Borkotoky S, Banerjee M
  • The rapid global spread of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has created an unprecedented healthcare crisis. The treatment for the severe respiratory illness caused by this virus is primarily symptomatic at this point, although the usage of a broad antiviral drug Remdesivir has been allowed on emergency basis by the Food and Drug Administration (FDA).The ever-increa…
  • Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. [Journal Article]
    N Engl J Med. 2020 May 27 [Online ahead of print]Goldman JD, Lye DCB, … GS-US-540-5773 Investigators
  • CONCLUSIONS: In patients with severe Covid-19 not requiring mechanical ventilation, our trial did not show a significant difference between a 5-day course and a 10-day course of remdesivir. With no placebo control, however, the magnitude of benefit cannot be determined. (Funded by Gilead Sciences; GS-US-540-5773 number, NCT04292899.).
  • Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking. [Journal Article]
    Biotechniques. 2020 May 27 [Online ahead of print]Cheng B, Li T
  • The outbreak of viral pneumonia caused by the novel coronavirus SARS-CoV-2 that began in December 2019 caused high mortality. It has been suggested that the main protease (Mpro) of SARS-CoV-2 may be an important target to discover pharmaceutical compounds for the therapy of this life-threatening disease. Remdesivir, ritonavir and chloroquine have all been reported to play a role in suppressing SA…
  • Can Zn Be a Critical Element in COVID-19 Treatment? [Review]
    Biol Trace Elem Res. 2020 May 26 [Online ahead of print]Rahman MT, Idid SZ
  • The current COVID-19 pandemic caused by SARS-CoV-2 has prompted investigators worldwide to search for an effective anti-viral treatment. A number of anti-viral drugs such as ribavirin, remdesivir, lopinavir/ritonavir, antibiotics such as azithromycin and doxycycline, and anti-parasite such as ivermectin have been recommended for COVID-19 treatment. In addition, sufficient pre-clinical rationale a…
  • Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19. [Review]
    Life Sci. 2020 May 23; 255:117842.Banerjee A, Czinn SJ, … Blanchard TG
  • The outbreak of COVID-19 caused by 2019-nCov/SARS-CoV-2 has become a pandemic with an urgent need for understanding the mechanisms and identifying a treatment. Viral infections including SARS-CoV are associated with increased levels of reactive oxygen species, disturbances of Ca++ caused by unfolded protein response (UPR) mediated by endoplasmic reticulum (ER) stress and is due to the exploitatio…
  • Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19. [Review]
    Pharmacotherapy. 2020 May 23 [Online ahead of print]Jorgensen SC, Kebriaei R, Dresser LD
  • The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective antivirals. Remdesivir (formerly GS-5734) is a nucleoside analogue pro-drug currently being evaluated in COVID-19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabol…
  • A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. [Review]
    FEBS J. 2020 May 23 [Online ahead of print]Atzrodt CL, Maknojia I, … Clements TP
  • The emergence of the SARS-CoV-2 strain of the human coronavirus has thrown the world into the midst of a new pandemic. In the human body, the virus causes COVID-19, a disease characterized by shortness of breath, fever, and pneumonia, which can be fatal in vulnerable individuals. SARS-CoV-2 has characteristics of past human coronaviruses, with close genomic similarities to SARS-CoV, the virus tha…
  • A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19. [Journal Article]
    Clin Pharmacol Ther. 2020 May 23 [Online ahead of print]Peck RW, Weiner D, … Powell JR
  • The SARS-CoV-2 pandemic and associated COVID-19 disease are straining healthcare systems around the world with large numbers of patients becoming ill in a very short period of time, overwhelming healthcare systems in many countries. Several drugs are being repurposed into clinical trials in COVID-19 patients, ranging from drugs already well established in other diseases, such as chloroquine/hydro…
  • Remdesivir for the Treatment of Covid-19 - Preliminary Report. [Journal Article]
    N Engl J Med. 2020 May 22 [Online ahead of print]Beigel JH, Tomashek KM, … ACTT-1 Study Group Members
  • CONCLUSIONS: Remdesivir was superior to placebo in shortening the time to recovery in adults hospitalized with Covid-19 and evidence of lower respiratory tract infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; ACCT-1 number, NCT04280705.).
  • Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More. [Journal Article]
    Arch Med Res. 2020 May 12 [Online ahead of print]Saha A, Sharma AR, … Chakraborty C
  • COVID-19 is now pandemic throughout the world. Scientist, doctors are searching for effective therapy of this diseases. The remdesivir, an antiviral drug, is appeared as 'molecule of hope' for the treatment of this disease. USFDA approve this drug for the treatment of COVID-19. The molecular mechanism is unknown. In this paper, we tried to describe the probable molecular mechanism of remdesivir t…
  • Structure of replicating SARS-CoV-2 polymerase. [Journal Article]
    Nature. 2020 May 21 [Online ahead of print]Hillen HS, Kokic G, … Cramer P
  • The coronavirus SARS-CoV-2 uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes1-3. Here we present the cryo-electron microscopic structure of the SARS-CoV-2 RdRp in active form, mimicking the replicating enzyme. The structure comprises the viral proteins nsp12, nsp8, and nsp7, and over two turns of RNA template-product duplex. The activ…
  • Novel 2019-coronavirus on new year's Eve. [Review]
    Indian J Med Microbiol. 2019 Oct-Dec; 37(4):459-477.Gupta P, Goyal K, … Singh MP
  • An ongoing apocalyptic outbreak of a new virus causing pneumonia-like clusters in Wuhan city, China, has gleamed the world. The outbreak, confirmed on the New Year's Eve 2020, has known no boundaries since then. The number has surpassed that of Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome (MERS), and is uninterruptedly escalating. Being an RNA virus, it has a prop…
  • Potential specific therapies in COVID-19. [Review]
    Ther Adv Respir Dis. 2020 Jan-Dec; 14:1753466620926853.Gul MH, Htun ZM, … Khan A
  • COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated co…
  • A novel coronavirus (SARS-CoV-2) and COVID-19. [Journal Article]
    Cas Lek Cesk. 2020 Spring; 159(2):55-66.Trojánek M, Grebenyuk V, … Stejskal F
  • By the end of 2019 the first cases of severe pneumonia of unknown origin were reported in Wuhan, China. The causative agent was identified as a novel b-coronavirus SARS-CoV-2 and the disease was named COVID-19. Since the beginning of 2020, the infection has spread worldwide, which led the WHO to declare COVID-19 a public health emergency of international concern and to characterize the current si…
New Search Next